

# Contents

---

Contributors xi

## PART I: PRINCIPLES OF CANCER IMMUNOBIOLOGY

### 1. Introduction 3

*George C. Prendergast and Elizabeth M. Jaffee*

- I. Overview 3
- II. Historical Background 3
- III. Looking Ahead: Marrying Chemotherapy and Immunotherapy 5
- IV. Parts of the Book 6
  - References 8
  - Further Reading 8

### 2. Cancer Immunoediting: From Immune Surveillance to Immune Escape 9

*Ryungsa Kim*

- I. Introduction 10
- II. Cancer Immune Surveillance 10
- III. Cancer Immunoediting 19
- IV. Concluding Remarks 25
  - References 25

### 3. Immunosurveillance: Innate and Adaptive Antitumor Immunity 29

*Masahisa Jinushi and Glenn Dranoff*

- I. Introduction 30
- II. Innate Antitumor Responses 30
- III. Innate Immune Cells 31
- IV. Adaptive Antitumor Responses 33
- V. The Interplay of Innate and Adaptive Antitumor Immunity 38
- VI. Conclusion 39
  - References 39

### 4. Cytokine Regulation of Immune Tolerance to Tumors 43

*Ming O. Li and Richard A. Flavell*

- I. Introduction 43
- II. Cytokine Regulation of Immune Tolerance to Tumors 45
- III. Summary and Future Perspectives 55
  - References 56

**5. Immunological Sculpting: Natural Killer Cell Receptors and Ligands 63***David A. Sallman and Julie Y. Djeu*

- I. Introduction 64
- II. Activating Human NK Receptors 65
- III. Inhibitory NK Receptors 72
- IV. The Ly49 Receptor Family 74
- V. Immunotherapy Approaches 74
- VI. Conclusion 77
- References 78
- Further Reading 80

**6. Immune Escape: Immunosuppressive Networks 83***Shuang Wei, Alfred Chang, and Weiping Zou*

- I. Introduction 83
- II. Imbalance Between Mature DCs and Immature DCs 84
- III. Imbalance Between Stimulatory and Inhibitory B7 Family Molecules 87
- IV. Imbalance Between Regulatory T Cells and Conventional T Cells 90
- V. Concluding Remarks 92
- References 92

**PART II: CANCER THERAPEUTICS****7. Cytotoxic Chemotherapy in Clinical Treatment of Cancer 101***Rajesh Thirumaran, George C. Prendergast, and Paul B. Gilman*

- I. Introduction 101
- II. DNA-Damaging Agents 103
- III. Antimetabolites 109
- IV. Antimitotics 112
- V. Chemotherapy Regimens 113
- References 115
- Useful Web Sites 116

**8. Targeted Therapeutics in Cancer Treatment 117***Colin D. Weekes and Manuel Hidalgo*

- I. Introduction 118
- II. Cell Cycle 119
- III. The MAPK Family 131
- IV. Challenges in the Clinical Development of Signal Transduction Inhibitors 136
- References 140

**9. Concepts in Pharmacology and Toxicology 149***Richard A. Westhouse and Bruce D. Car*

- I. Introduction 150
- II. Concepts in Pharmacokinetics 151
- III. Concepts in Toxicology 159

- IV. Clinical Concerns for Pharmacology and Safety 164
- V. Conclusion 165
- References 165
- Further Reading 166

## 10. Cancer Immunotherapy: Challenges and Opportunities 167

*Andrew J. Lepisto, John R. McKolanis, and Olivera J. Finn*

- I. Introduction 168
- II. Prerequisites for Effective Cancer Immunotherapy: Identifying Tumor Antigens 168
- III. Adoptive ("Passive") Immunotherapy 169
- IV. Active-Specific Immunotherapy: Vaccines 171
- V. Cancer-Induced Immunosuppression Impinges on Immunotherapy 172
- VI. Cancer Immunotherapy in Mice Versus Humans 175
- VII. Immunotherapy and Cancer Stem Cells 176
- VIII. Autoimmunity Resulting from Cancer Immunotherapy 176
- IX. Conclusion and Future Considerations 177
- References 178

## 11. Cancer Vaccines 183

*Freda K. Stevenson, Gianfranco Di Genova, Christian Ottensmeier, and Natalia Savelyeva*

- I. Introduction 184
- II. Tumor Antigens 185
- III. Spontaneous Immunity to Cancer 187
- IV. Tolerogenic Pressure on Immunity to Cancer 187
- V. Immune Responses to Conventional Vaccines 189
- VI. Cancer Vaccine Strategies 194
- VII. DNA Vaccines 195
- VIII. Challenges of Translation to the Clinic 199
- IX. Concluding Remarks 200
- References 200
- Further Reading 204

## PART III: TARGETS AND TACTICS TO IMPROVE CANCER IMMUNOTHERAPY BY DEFEATING IMMUNE SUPPRESSION

## 12. Immunotherapy and Cancer Therapeutics: Why Partner? 207

*Leisha A. Emens and Elizabeth M. Jaffee*

- I. Introduction: Why Immunotherapy for Cancer? 208
- II. Immune Tolerance and Suppression: Multiple Layers of Negative Control 209
- III. T Cell Activation: A Rheostat for Tuning Immune Responses 212
- IV. Immune Modulation with Therapeutic Monoclonal Antibodies 219
- V. Therapeutics that Mitigate the Influence of CD4<sup>+</sup>CD25<sup>+</sup> Tregs 222
- VI. Endocrine and Biologically Targeted Therapy 224
- VII. Conclusion 225
- References 225

**13. Immune Stimulatory Features of Classical Chemotherapy 235***Robbert G. van der Most, Anna K. Nowak, and Richard A. Lake*

- I. Introduction 236
- II. Tumor Cell Death 236
- III. Pathways to Immunogenicity 239
- IV. Chemotherapy and the Immune System 243
- V. A Practical Partnership: Chemotherapy and Immunotherapy 246
- VI. Effects of Chemotherapy on Human Antitumor Immunity and Chemoimmunotherapy Clinical Trials 250
- References 252

**14. Dendritic Cells and Coregulatory Signals: Immune Checkpoint Blockade to Stimulate Immunotherapy 257***Drew Pardoll*

- I. Regulation of T Cell Responses to Antigen 258
- II. Regulatory T Cells 261
- III. Immune Checkpoints in the Tumor Microenvironment 262
- IV. Monoclonal Antibodies that Interfere with Coinhibitory Receptors on T Cells 266
- V. What Is the Most Effective Way to Use Checkpoint Inhibitors? 269
- References 270

**15. Regulatory T Cells in Tumor Immunity: Role of Toll-Like Receptors 277***Rong-Fu Wang*

- I. Introduction 278
- II. Immune Cells in Immunosurveillance and Tumor Destruction 278
- III. TLRs and Their Signaling Pathways 279
- IV. TLRs in Innate Immunity, Inflammation, and Cancer Development 280
- V. Tumor-Infiltrating Immune Cells in the Tumor Microenvironment 281
- VI. Molecular Marker for CD4<sup>+</sup> Tregs 282
- VII. Antigen Specificity of CD4<sup>+</sup> Tregs 282
- VIII. Suppressive Mechanisms of Tregs 283
- IX. Functional Regulation of Tregs and Effector Cells by TLR Signaling 283
- X. Implications for Enhancing Antitumor Immunity 284
- XI. Conclusion 285
- References 285

**16. Tumor-Associated Macrophages in Cancer Growth and Progression 289***Alberto Mantovani, Paola Allavena, and Antonio Sica*

- I. Introduction 289
- II. Macrophage Polarization 290
- III. Macrophage Recruitment at the Tumor Site 291
- IV. Tam Expression of Selected M2 Protumoral Functions 294
- V. Modulation of Adaptive Immunity by Tams 296
- VI. Targeting Tams 297
- VII. Concluding Remarks 300
- References 302



**17. Tumor-Associated Myeloid-Derived Suppressor Cells 309**

*Stephanie K. Bunt, Erica M. Hanson, Pratima Sinha, Minu K. Srivastava,  
Virginia K. Clements, and Suzanne Ostrand-Rosenberg*

- I. Introduction 310
- II. Multiple Suppressive Mechanisms that Contribute to Immunosuppression in Individuals with Tumors 310
- III. MDSCs as a Key Cell Population that Mediates Tumor-Induced Immunosuppression 311
- IV. MDSCs' Use of Mechanisms to Mediate Effects on Multiple Target Cells 317
- V. MDSC Induction by Tumor-Derived Cytokines and Growth Factors 321
- VI. MDSC Linking of Inflammation and Tumor Progression 322
- VII. Agents Responsible for Reducing MDSC Levels 323
- VIII. Conclusions: Implications for Immunotherapy 326
- References 327
- Further Reading 331

**18. Programmed Death Ligand-1 and Galectin-1: Pieces in the Puzzle of Tumor-Immune Escape 333**

*Gabriel A. Rabinovich and Thomas F. Gajewski*

- I. Programmed Death Ligand 1 and Programmed Death 1 Interactions 334
- II. Galectin 1 338
- References 344
- Further Reading 346

**19. Indoleamine 2,3-Dioxygenase in Immune Escape: Regulation and Therapeutic Inhibition 347**

*Alexander J. Muller and George C. Prendergast*

- I. Introduction 348
- II. IDO Function in T Cell Regulation 351
- III. Complex Control of IDO by Immune Regulatory Factors 351
- IV. Immune Tolerance Via IDO in Dendritic Cells 353
- V. IDO Dysregulation in Cancer Cells 357
- VI. IDO as a Target for Therapeutic Intervention 359
- VII. Discovery and Development of IDO Inhibitors 360
- VIII. Conclusion 361
- References 362
- Further Reading 368

**20. Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-Arginine Metabolism in Immune Modulation 369**

*Susanna Mandruzzato, Simone Mocellin, and Vincenzo Bronte*

- I. Introduction 370
- II. NOS: Genes, Regulation, and Activity 371
- III. ARG: Genes, Regulation, and Activity 372
- IV. Immunoregulatory Activities of ARG and NOS 374
- V. Possible Physiological Role for L-ARG Metabolism in Immunity Control 381
- VI. NOS in Cancer 382

VII.	ARG in Cancer	384
VIII.	ARG and NOS Inhibitors: A Novel Class of Immune Adjuvants?	386
IX.	Conclusion and Perspectives	388
	References	389
	Further Reading	399
<b>Index</b>		<b>401</b>